Neeraj Adya
Head, Diagnostics, Immunology J&J Innovative Medicine
Seminars
Wednesday 7th October 2026
MRD in IBD? Building a Precision Medicine Consortium for Deeper Endpoints in IBD
12:50 pm
- Precision medicine transformed oncology by enabling patient segmentation, molecular monitoring, and the adoption of more sensitive endpoints such as minimal residual disease. Can inflammatory bowel disease be next?
- In this joint presentation, Johnson & Johnson Innovative Medicines and the Crohn's & Colitis Foundation explore how precision medicine and diagnostics approaches can advance IBD beyond traditional remission endpoints toward deeper measures of disease control
- The session proposes a pre-competitive consortium model that brings together industry, foundations, diagnostic developers, and data partners to standardize endpoints, harmonize biospecimen and data strategies, and accelerate the development of clinically actionable biomarkers and Rx-Dx solutions
